

CITATION REPORT

List of articles citing

Targeting BTK in CLL: Beyond Ibrutinib

DOI: 10.1007/s11899-019-00512-0

Current Hematologic Malignancy Reports, 2019, 14, 197-205.

Source: <https://exaly.com/paper-pdf/73363592/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
88	The evolving treatment landscape of chronic lymphocytic leukemia. <i>Current Opinion in Oncology</i> , 2019 , 31, 568-573	4.2	7
87	Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. <i>Blood Reviews</i> , 2020 , 40, 100635	11.1	20
86	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. <i>Nature Communications</i> , 2020 , 11, 5214	17.4	104
85	Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. <i>Expert Review of Hematology</i> , 2020 , 13, 871-883	2.8	5
84	Next-Generation Bruton Tyrosine Kinase Inhibitors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2937-2940	2.2	1
83	Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. <i>Acta Haematologica</i> , 2021 , 144, 365-379	2.7	5
82	Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. <i>Hematology American Society of Hematology Education Program</i> , 2020 , 2020, 33-40	3.1	4
81	Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche. <i>Cancer Management and Research</i> , 2020 , 12, 5857-5879	3.6	7
80	Second cancer incidence in CLL patients receiving BTK inhibitors. <i>Leukemia</i> , 2020 , 34, 3197-3205	10.7	20
79	HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development. <i>Bioorganic Chemistry</i> , 2020 , 105, 104377	5.1	2
78	Mantle cell lymphoma: insights into therapeutic targets at the preclinical level. <i>Expert Opinion on Therapeutic Targets</i> , 2020 , 24, 1029-1045	6.4	1
77	Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 10726-10741	8.3	11
76	Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 709-722	5.9	4
75	Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	10
74	Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects. <i>OncoTargets and Therapy</i> , 2020 , 13, 4877-4892	4.4	8
73	Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape. <i>Current Treatment Options in Oncology</i> , 2020 , 21, 24	5.4	22
72	Noncatalytic Bruton's tyrosine kinase activates PLC β variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells. <i>Journal of Biological Chemistry</i> , 2020 , 295, 5717-5736	5.4	16

71	The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?. <i>Expert Review of Hematology</i> , 2020 , 13, 771-779	2.8	2
70	Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease. <i>Molecules</i> , 2020 , 25,	4.8	32
69	Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
68	BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining. <i>Frontiers in Oncology</i> , 2020 , 10, 424	5.3	50
67	Der Stand der Therapie bei der refraktären/rezidivierenden chronischen lymphatischen Leukämie: Neuartige Wirkstoffe im Fokus. <i>Karger Kompass Onkologie</i> , 2021 , 8, 59-69	0	
66	Current and novel BTK inhibitors in Waldenström's macroglobulinemia. <i>Therapeutic Advances in Hematology</i> , 2021 , 12, 2040620721989586	5.7	4
65	Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2021 , 5, 334-343	7.8	9
64	Activation of Interferon Signaling in Chronic Lymphocytic Leukemia Cells Contributes to Apoptosis Resistance via a JAK-Src/STAT3/Mcl-1 Signaling Pathway. <i>Biomedicines</i> , 2021 , 9,	4.8	2
63	Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. <i>Cancers</i> , 2021 , 13,	6.6	16
62	Novel synthetic drugs for the treatment of non-Hodgkin lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1417-1427	4	2
61	Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 630942	5.7	37
60	Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 40	22.4	18
59	Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1395-1399	7	34
58	Leucémie lymphoïde chronique : de la biologie à la thérapeutique. <i>Revue Francophone Des Laboratoires</i> , 2021 , 2021, 32-43	0	
57	BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. <i>Blood</i> , 2021 , 138, 1843-1854	2.2	3
56	p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 690365	5.7	4
55	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
54	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3441-3452	2.2	65

53	Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. <i>Blood</i> , 2021 , 138, 1099-1109	2.2	2
52	Acute gout flare of bilateral first metatarsophalangeal joints due to ibrutinib use in chronic lymphocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 10781552211029703	1.7	1
51	The future of antibody therapy in chronic lymphocytic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 26, 323-336	3.7	0
50	Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. <i>Frontiers in Immunology</i> , 2021 , 12, 694853	8.4	9
49	Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse. <i>Seminars in Oncology Nursing</i> , 2021 , 37, 151177	3.7	0
48	The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. <i>Current Opinion in Oncology</i> , 2021 , 33, 670-680	4.2	0
47	The role of Bruton's tyrosine kinase in the immune system and disease. <i>Immunology</i> , 2021 , 164, 722-736	7.8	10
46	Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. <i>Cancer Medicine</i> , 2021 , 10, 7629-7640	4.8	5
45	Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. <i>Haematologica</i> , 2021 ,	6.6	5
44	Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 47, 116358	3.4	8
43	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. 2020 ,		16
42	Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020 , 1, 131-152	2.5	9
41	Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia. <i>Current Oncology</i> , 2020 , 27, e645-e655	2.8	2
40	Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations. <i>Pharmaceutics</i> , 2021 , 13,	6.4	0
39	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma. <i>Hematological Oncology</i> , 2021 , 39, 605-615	1.3	1
38	The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 923-935	3	4
37	Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy. <i>Medicinal Chemistry Research</i> , 2021 , 1-25	2.2	1
36	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. <i>European Journal of Medicinal Chemistry</i> , 2021 , 229, 114009	6.8	7

35	Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia).. <i>Advances in Hematology</i> , 2022 , 2022, 1182384	1.5	0
34	The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.. <i>Cancers</i> , 2022 , 14,	6.6	11
33	Design and synthesis of novel pyrazolopyrimidine-based derivatives as reversible BTK inhibitors with potent antiproliferative activity in mantle cell lymphoma. <i>Medicinal Chemistry Research</i> , 2022 , 31, 594-604	2.2	
32	Druggable Molecular Pathways in Chronic Lymphocytic Leukemia.. <i>Life</i> , 2022 , 12,	3	
31	A Novel Finding of Lichenoid Drug Reaction From Ibrutinib Therapy.. <i>Cureus</i> , 2022 , 14, e22433	1.2	
30	The Mysterious Actor- π Lymphocytes in Chronic Lymphocytic Leukaemia (CLL).. <i>Cells</i> , 2022 , 11,	7.9	0
29	Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.. <i>Leukemia and Lymphoma</i> , 2022 , 1-8	1.9	0
28	Recent development of BTK-based dual inhibitors in the treatment of cancers.. <i>European Journal of Medicinal Chemistry</i> , 2022 , 233, 114232	6.8	1
27	Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors.. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022 , 37, 226-235	5.6	0
26	Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.. <i>Expert Review of Hematology</i> , 2022 ,	2.8	2
25	Data_Sheet_1.PDF. 2020 ,		
24	Table_1.DOCX. 2020 ,		
23	Table_2.DOCX. 2020 ,		
22	Table_3.docx. 2020 ,		
21	[F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase.. <i>Molecular Imaging and Biology</i> , 2022 , 1	3.8	0
20	Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. <i>Blood Reviews</i> , 2022 , 100971	11.1	0
19	Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance. <i>Journal of Medicinal Chemistry</i> ,	8.3	1
18	Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2022 , 6, e729	0.3	

17	BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. <i>Cellular Signalling</i> , 2022 , 96, 110358	4.9
16	Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022 , 37, 1667-1693 ^{5,6}	1
15	Next-generation Bruton's tyrosine kinase (BTK) inhibitors potentially targeting BTK C481S mutation- Recent developments and Perspectives.. 2022 , 22,	2
14	Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.	0
13	Platelets and tyrosine kinase inhibitors: clinical features, mechanism of action and effects on physiology.	0
12	Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect. 2022 , 11,	0
11	Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux. 2022 , 14, 1994	0
10	Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases. 2022 ,	0
9	Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo. 2022 , 21, 153303382211332	0
8	Immunotherapy approaches for hematological cancers. 2022 , 25, 105326	0
7	Development of novel hydrazidoarylamino-pyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects. 2023 , 245, 114913	0
6	Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review. 12,	0
5	Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia. 12,	0
4	BMX controls 3HSD1 and sex steroid biosynthesis in cancer. 2023 , 133,	0
3	Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma. 2023 , 943, 175526	0
2	2-Arachidonoylglycerol Modulates CXCL12-Mediated Chemotaxis in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. 2023 , 15, 1585	0
1	Case report: Synergistic defects of CASP10 and BTK leading to autoimmune lymphoproliferative syndrome type IIa, complicated by severe hemophagocytic lymphohistiocytosis.	0